Pancreatic Cancer: Translating Tumor Biology into Actionability
Cancer Discovery · 01.07.2026 · 16 (7) · 1262-1279
DOI: 10.1158/2159-8290.cd-25-2014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Discovery, online erschienen am 01.07.2026. Verfasst von Fiyinfolu O Balogun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute (NCI).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents. Significance: PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Medicine, Weill Cornell Medicine, New York, New York.
- Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID-Profile: Fiyinfolu O Balogun, Mara H Sherman, Wungki Park, Kevin C Soares, Marsha Reyngold, Joshua D Schoenfeld, Anupriya Singhal, Christine A Iacobuzio-Donahue, Eileen M O'Reilly
Förderung
- NCI NIH HHS
- National Cancer Institute (NCI)
Zitieren
APA
Balogun, F. O., Sherman, M. H., Park, W., Soares, K. C., Reyngold, M., Schoenfeld, J. D., Singhal, A., Iacobuzio-Donahue, C. A., & O'Reilly, E. M. (2026). Pancreatic Cancer: Translating Tumor Biology into Actionability. Cancer Discovery, 16(7), 1262-1279. https://doi.org/10.1158/2159-8290.cd-25-2014
Vancouver
Balogun FO, Sherman MH, Park W, Soares KC, Reyngold M, Schoenfeld JD, et al. Pancreatic Cancer: Translating Tumor Biology into Actionability. Cancer Discovery. 2026;16(7):1262-1279. doi:10.1158/2159-8290.cd-25-2014
BibTeX
@article{Balogun2026,
author = {Balogun, Fiyinfolu O and Sherman, Mara H and Park, Wungki and Soares, Kevin C and Reyngold, Marsha and Schoenfeld, Joshua D and Singhal, Anupriya and Iacobuzio-Donahue, Christine A and O'Reilly, Eileen M},
title = {Pancreatic Cancer: Translating Tumor Biology into Actionability},
journal = {Cancer Discovery},
year = {2026},
volume = {16},
number = {7},
pages = {1262--1279},
doi = {10.1158/2159-8290.cd-25-2014}
}
EUVIMED